Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KORU Medical SystemsKRMD -1.83%80 EBITDA Margin % is 6.95% as of Jun. 2026. GuruFocus rates KRMD with a GF Score™ of 80/100 and a GF Value™ of $4.01 (Modestly Undervalued). Among 814 Medical Devices & Instruments companies, KORU Medical Systems ranks worse than 63.14% on this metric.
KORU Medical Systems (NAS:KRMD) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
KORU Medical Systems EBITDA Margin % Related Terms
KORU Medical Systems EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for KORU Medical Systems's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KRMD vs PDEX, EMBC, UTMD: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, KORU Medical Systems's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KORU Medical Systems EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, KORU Medical Systems's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where KORU Medical Systems's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KORU Medical Systems (KRMD) has a EBITDA Margin % of 6.95% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on KORU Medical Systems and its competitors. According to the industry distribution chart, KORU Medical Systems ranks #514 out of 814 companies in the Medical Devices & Instruments industry, placing it in the top 63.1%.
Is KORU Medical Systems' EBITDA Margin % too high?
KORU Medical Systems' current EBITDA Margin % is 6.95%. The Medical Devices & Instruments industry median EBITDA Margin % is 8.07. KORU Medical Systems' value of 6.95% is 13.8% below this industry median. Based on the distribution chart, KORU Medical Systems ranks #514 out of 814 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, KORU Medical Systems has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does KORU Medical Systems' EBITDA Margin % compare to PDEX and EMBC?
According to the Medical Devices & Instruments industry distribution chart, KORU Medical Systems ranks #514 out of 814 companies for EBITDA Margin %. This places KORU Medical Systems in the lower half of its industry. The industry median EBITDA Margin % is 8.07. KORU Medical Systems' value of 6.95% is 13.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 8.07, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. KORU Medical Systems's current EBITDA Margin % of 6.95% is 13.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on KORU Medical Systems and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 8.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KORU Medical Systems's current EBITDA Margin % is 6.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KORU Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, KORU Medical Systems (KRMD) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.01, compared to a current price of $3.22 — trading 19.7% below its estimated fair value. The current EBITDA Margin % is 6.95% and 13.8% below the Medical Devices & Instruments industry median of 8.07. KORU Medical Systems' overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For KORU Medical Systems (KRMD), the current EBITDA Margin % is 6.95% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KORU Medical Systems (KRMD) Overvalued in 2026?
Based on GuruFocus' analysis, KORU Medical Systems stock appears to be undervalued.
The current stock price of $3.22 is trading 19.7% below its estimated GF Value™ of $4.01.
GuruFocus considers KORU Medical Systems to be Modestly Undervalued.
Key valuation signals for KRMD:
EBITDA Margin %: 6.95%
GF Value™: $4.01 vs. price of $3.22 (19.7% below fair value)
Industry Position: 13.8% below the Medical Devices & Instruments median (#514 of 814)
No single metric tells the full story. See the KRMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
80GF Score
Get the complete analysis for KRMD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KRMD has been successfully added to your 
